Table 1.
Patient characteristics
| Subjects n (%)a |
Median survival Months (IQR) |
1-Year survival (%) | 2-Year survival (%) | p value | |
|---|---|---|---|---|---|
| Overall | 566 (100) | 4.5 (1.5–11.6) | 24 | 15 | – |
| Gender | |||||
| Men | 420 (74) | 3.6 (1.3–8.1) | 17 | 10 | < 0.001 |
| Women | 146 (26) | 8.9 (2.8–33.1) | 45 | 30 | |
| Age (years) | |||||
| 0–64 | 197 (35) | 7.3 (2.7–26.6) | 40 | 27 | < 0.001 |
| 65–74 | 199 (35) | 4.6 (1.7–9.5) | 19 | 11 | |
| 75+ | 170 (30) | 1.9 (0.9–6.9) | 12 | 6 | |
| EOD stage | |||||
| Local | 172 (30) | 5.4 (1.8–14.9) | 28 | 17 | 0.102 |
| Regional | 136 (24) | 5.0 (1.4–12.2) | 26 | 15 | |
| Distant | 111 (20) | 3.6 (1.1–10.8) | 20 | 14 | |
| Unknown | 147 (26) | 3.1 (1.5–9.9) | 20 | 14 | |
| Period | |||||
| 1993–2000 | 166 (29) | 4.5 (1.4–7.7) | 17 | 10 | 0.02 |
| 2001–2008 | 195 (34) | 3.8 (1.5–11.3) | 23 | 13 | |
| 2009–2016 | 205 (36) | 5.0 (1.6–18.6) | 31 | 20 | |
| Morphology | |||||
| Epithelioid | 324 (57) | 5.0 (1.2–8.0) | 27 | 18 | 0.02 |
| Sarcomatoid | 14 (2) | 2.0 (1.1–12.0) | 29 | 14 | |
| Biphasic | 31 (5) | 3.4 (1.8–14.9) | 13 | 9 | |
| NOS | 197 (35) | 3.6 (1.2–8.1) | 20 | 11 | |
| Therapy | |||||
| Chemotherapy | 117 (21) | 8.8 (5.0–17.1) | 36 | 18 | < 0.001 |
| Surgery ± chemo | 43 (8) | 15.5 (4.7–67.1) | 56 | 44 | |
| HIPEC ± CRS | 28 (5) | 23.4 (6.9–83.6) | 68 | 50 | |
| Other/BSC | 378 (67) | 2.5 (1.1–6.7) | 13 | 8 | |
IQR interquartile range, EOD extent of disease classification, NOS not otherwise specified, HIPEC hyperthermic intraperitoneal chemotherapy, CRS cytoreductive surgery
aPercentages in the subjects column do not add up to 100% due to rounding